Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-05

Clinical Trial Update: Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of everolimus with or without trastuzumab in hormone-refractory metastatic breast cancer completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Everolimus (everolimus)
  • Trastuzumab (trastuzumab)

Snippet

Sponsor: Emory University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-05